MedTrace Logo

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors

NCT06392789 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-06

No results posted yet for this study

Summary

This clinical trial evaluates the effect of conversational agent, Cecebot, on improving insomnia in stage I-III breast cancer survivors. Sleep disturbance ranks among the top concerns reported by breast cancer survivors and is associated with poor quality of life. Many breast cancer survivors also have decreased physical activity, which may also have a negative impact on sleep and quality of life. Cognitive behavioral therapy for insomnia (CBTi) and physical activity interventions have individually been reported to improve sleep and to have a positive impact on quality of life. Cecebot is a personalized short messaging service (SMS)-based behavioral intervention that combines CBTi and physical activity strategies that may improve sleep for breast cancer survivors.

Conditions

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Insomnia

Interventions

BEHAVIORAL

Cognitive Behavior Therapy for Insomnia

Receive sleep education

OTHER

Internet-Based Intervention

Receive access to website content modules

OTHER

Medical Device Usage and Evaluation

Wear activity tracker

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Text Message-Based Navigation Intervention

Receive sleep compression SMS conversations

Sponsors & Collaborators

Principal Investigators

  • Kerryn Reding · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-04
Primary Completion
2026-01-16
Completion
2026-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06392789 on ClinicalTrials.gov